

The insulin signaling pathway is dysregulated in cumulus cells from obese, infertile women with polycystic ovarian syndrome with an absence of clinical insulin resistance

Mauricio B. Chehin , Renato Fraietta, Aline R. Lorenzon, Tatiana C.S. Bonetti and Eduardo L.A. Motta

Abstract

Methods: This is a cohort study, conducted at a university-based reproductive medicine center and private reproductive medicine center that aimed to evaluate granulosa cumulus cell gene expression in the insulin signaling pathway in Polycystic Ovary Syndrome (PCOS) patients undergoing in vitro fertilization (IVF) treatment and to compare the cumulus gene expression between normal weight and obese women without clinical insulin resistance. Fifteen PCOS patients, nine normal weight patients and six obese patients presenting normal HOMA IR (Homeostasis Model Assessment–Insulin Resistance), participated. Patients underwent oocyte retrieval for IVF and after the procedure, granulosa cumulus cells were removed from the oocytes for RNA extraction. Quantitative polymerase chain reaction (PCR) array analysis of 84 genes from insulin signaling pathway was conducted. The results were expressed as fold up- or fold down-expression in obese patients compared with normal weight patients. Any fold change ≥ 3 or ≤ 3 and any $p \leq 0.05$ were considered statistically significant.

Results: There were 10 genes that were overexpressed in obese compared with normal weight women, BCL2L1, BRAF, CBL, DOK1, FBP1, FRS2, MTOR, PCK2, RPS6KA1, and SORBS1, that had a fold change ≥ 3 and $p \leq 0.05$.

Discussion: In the obese group, the overexpressed genes are mainly responsible for the proliferation and differentiation of cumulus cells during oocyte maturation, insulin resistance, apoptosis regulation, and glucose metabolism during early embryogenesis, suggesting that in the follicular environment, insulin resistance is present even in the absence of clinical signs.

Conclusion: Together, our findings and the related literature suggest that those alterations may be associated with the worse prognosis of follicular development and oocyte maturation observed in PCOS obese women.

Keywords: cumulus cells, gene expression, *in vitro* fertilization, insulin, obesity, Polycystic Ovary Syndrome

Received: 3 May 2019; revised manuscript accepted: 20 January 2020.

Introduction

Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder during the reproductive age,^{1,2} affecting 5% to 10% of women,³ and is one of the main causes of infertility.^{4,5} According to the Rotterdam criteria, PCOS is characterized

by two of the following three features: (1) clinical and/or biochemical hyperandrogenism, (2) oligo- and/or anovulation, and (3) polycystic ovaries, excluding other endocrinopathies such as congenital adrenal hyperplasia, androgen-secreting tumors, and Cushing's syndrome.⁶

Ther Adv Reprod Health

2020, Vol. 14: 1–10

DOI: 10.1177/
2633494120906866

© The Author(s), 2020.
Article reuse guidelines:
sagepub.com/journals-
permissions

Correspondence to:

Mauricio B. Chehin
Huntington Medicina
Reprodutiva, Medical
Coordinator Vila Mariana,
Rua Sena Madureira, 100,
São Paulo, SP 04021-000,
Brazil

Gynecology Endocrinology
Discipline, Gynecology
Department, Escola
Paulista de Medicina da
Universidade Federal de
Sao Paulo (UNIFESP-
EPM), São Paulo, Brazil

**mchehin@huntington.
com.br**

Renato Fraietta
Human Reproduction
Section, Surgery
Discipline, Urology
Department Escola
Paulista de Medicina da
Universidade Federal de
São Paulo (UNIFESP-
EPM), São Paulo, Brazil

Aline R. Lorenzon
Huntington Medicina
Reprodutiva, São Paulo,
Brazil

Tatiana C.S. Bonetti
Gynecology Endocrinology
Discipline, Gynecology
Department, Escola
Paulista de Medicina da
Universidade Federal de
Sao Paulo (UNIFESP-
EPM), São Paulo, Brazil

Eduardo L.A. Motta
Gynecology Endocrinology
Discipline, Gynecology
Department, Escola
Paulista de Medicina da
Universidade Federal de
Sao Paulo (UNIFESP-
EPM), São Paulo, Brazil
Huntington Medicina
Reprodutiva, São Paulo,
Brazil

Approximately 50% of women with PCOS are obese⁷ and often present with severe metabolic disturbances, and the most severe phenotypes are linked to insulin resistance.⁸ Those patients who undergo *in vitro* fertilization (IVF) show a large number of immature oocytes, poor embryo quality, miscarriages, and a higher incidence of Ovarian Hyperstimulation Syndrome (OHSS) when compared with non-PCOS patients of the same age.^{9,10} Adverse perinatal outcomes and lower pregnancy rates are observed in obese compared with non-obese PCOS patients.^{11,12}

Although the etiology of PCOS remains unclear,^{13,14} the concept of a multifactorial disorder with candidate genes involved in steroidogenic and metabolic pathways has been explored to elucidate the genetic predisposition profile.¹⁵ Multiple genes, environmental factor interactions, and most recently hormones, such as Anti-Müllerian Hormone, may contribute to the complexity of this syndrome.^{13,16} However, at present, there is no consensus on genetic susceptibility markers for PCOS.¹⁷

Insulin is well known to play a central role in PCOS, mainly in obese women, and cross-reacts with the insulin-like growth factor 1 (IGF-1) receptor to enhance ovarian and adrenal steroidogenesis, activating tyrosine kinase phosphorylation and several intracellular signaling cascades.¹⁸ The precise mechanism of insulin action on cumulus cells (CCs) and the consequences for oocyte maturation have not been completely elucidated in obese or non-obese PCOS patients.

Because the CCs, a subset of granulosa cells that maintain an intimate connection with the oocyte, are responsible for providing several trophic and metabolic factors to the pre-ovulatory oocyte,¹⁹ we hypothesized that assessing insulin pathway gene expression in these cells could provide another perspective on the pathophysiology and possible treatment for infertile PCOS obese women submitted to IVF who did not exhibit clinical insulin resistance. The aim of this study was to investigate the insulin pathway gene expression profile of human CCs from obese *versus* normal weight women with PCOS without clinical insulin resistance undergoing IVF treatment.

Methods

This prospective cohort study was carried out at the Human Reproduction Section of Federal University of São Paulo and Huntington Reproductive Medicine from January 2013 to October 2014. This study was approved by the Institutional Review Board of the Federal University of São Paulo (protocol number 1420/09, São Paulo, Brazil), and written informed consent was obtained from all participants.

Study population and CC sample collection

The study population included 15 infertile PCOS women undergoing IVF treatment, including 9 women with normal body mass index (BMI; between 18.5 and 25.0 kg/m²) in the PCOS-Normal weight group (PCOS-NORM Group) and 6 obese women with BMI \geq 30.0 kg/m² in the PCOS-Obese group (PCOS-OB Group). The sample size was based on a previous study.²⁰ PCOS was diagnosed according to the Rotterdam criteria.⁶ We excluded PCOS women with Homeostasis Model Assessment–Insulin Resistance (HOMA IR) $>$ 3.6 for normal BMI women (BMI = 18.5–25 kg/m²) and $>$ 4.7 for obese women,^{20,21} as well as women who were underweight (BMI $<$ 18.5 kg/m²), overweight (BMI = 25.1–29.9 kg/m²), had other endocrine diseases (such as diabetes or thyroid dysfunctions), received hormonal treatment before IVF, had repeated miscarriages, used insulin sensitizers, or were diagnosed with endometriosis. Both PCOS-NORM and PCOS-OB patients underwent controlled ovarian stimulation using a GnRH antagonist combined with recombinant follicle stimulating hormone (FSH) (r-FSH) and intracytoplasmic sperm injection (ICSI).

Briefly, women started ovarian stimulation with 225 IU of r-FSH (Gonal; Serono) beginning on day 3 of the menstrual cycle. The GnRH antagonist (Cetrorelix, 0.25 mg) was initiated when follicular size was 14 mm in diameter or on day 7 of ovarian stimulation. The final oocyte maturation trigger was 250 mcg human Chorionic Gonadotropin (hCG, Ovidrel; Serono, Darmstadt, Germany) once at least one follicle reached 20 mm. Estradiol levels were below 3500 pg/ml and there was no OHSS. Cumulus oocyte complexes were retrieved by vaginal puncture and guided by transvaginal ultrasound 35 h after hCG administration.

Pooled cumulus oocyte complexes from each patient were collected in G-MOPS medium (3-N-morpholino) propanesulfonic acid buffered medium, Vitrolife, Gothenburg, Sweden), and CCs, which also include corona radiata cells, were mechanically stripped from oocytes under magnifying glass using two disposable needles and two 1-ml plastic disposable syringes without hyaluronidase. The number of CCs collected was similar between groups. The mature oocytes were used for the ICSI procedure, and pooled CCs from each patient were immediately frozen at -80°C in RNA for later analysis.

RNA isolation and gene expression analysis

Total RNA was isolated from CCs using the Trizol method (Trizol™ reagent, Thermo Fisher Scientific, Grand Island, NY, USA) according to the manufacturer's instructions. The RNA concentration and quality (260/280 ratio) were assessed using a spectrophotometer (NanoDrop 2000 instrument, Thermo Scientific, Waltham, MA, USA). Then, 100 ng of total RNA was used for reverse transcription to generate double-stranded complementary DNA (cDNA) using an RT² First Strand Kit (Qiagen, Germantown, MD, USA) according to the manufacturer's instructions.

Real-time quantitative polymerase chain reaction (RT-qPCR) assays were performed to evaluate 84 genes related to the insulin signaling pathway (RT² Profiler™ PCR Array Human Insulin Signaling Pathway—PAHS-030ZC, Qiagen), and pre-designed assays were used to carry out quantitative PCR (7500 Real-Time PCR System, Applied Biosystems, Foster City, CA, USA). The specific pathway function for each gene is described in Supplemental Data 1. The 96-well PCR array plates contain five house-keeping genes (actin beta—ACTB, beta-2-microglobulin—B2M, glyceraldehyde-3-phosphate dehydrogenase—GAPDH, hypoxanthine phosphoribosyltransferase-1—HPRT1, ribosomal protein large P0—RPLP0) and a panel of patented controls to monitor genomic DNA contamination, strand cDNA synthesis, and real-time PCR efficiency. The PCR array plates were assayed using a Step One Plus Real-Time PCR System (Applied Biosystems). We obtained cycle threshold (Ct) values for the genes under investigation, and the $\Delta\Delta\text{Ct}$ method was used for

gene expression analysis using the PCR Array Data Analysis Web Portal (<https://dataanalysis.sabiosciences.com/pcr/arrayanalysis.php>).

Statistical analysis

All statistical analyses were performed considering $n=6$ for obese group and $n=9$ for normal weight group. Differences in gene expression were calculated by the delta Ct method by using the RT² Profiler PCR Data Analysis (<https://www.qiagen.com/us/shop/genes-and-pathways/data-analysis-center-overview-page/>). The significance of the expression differences in the two groups was calculated using Mann-Whitney *U* test. The results were expressed as fold up- or fold down-expression in PCOS-OB compared with that in PCOS-NORM. Genes that had expression levels with a fold change (FC) of at least ≥ 3 or ≤ 3 and $p \leq 0.05$ were considered differentially expressed (DE). The DE genes were analyzed using Advaita Bio's iPathwayGuide (<http://www.advaitabio.com/ipathwayguide>), and the significantly impacted pathways, biological processes, and molecular functions were analyzed. To detect the Gene Ontology (GO) categories that were over- or under-represented in the condition under study, we used Advaita Bio's iPathwayGuide, which uses an impact analysis method that relies on classical statistics and also considers other key factors such as the magnitude of the expression change for each gene, their type and position on the given pathways, and their interactions. The Elim pruning method, which iteratively removes the genes mapped to a significant GO term from more general (higher level) GO terms, was used to overcome the limitation of errors introduced by considering genes multiple times. The settings used were as follows: log-FC = 0.6 and adjusted p value = 0.05.

Results

Patient characteristics

The patients' demographic and clinical profiles are described in Table 1. Except for BMI, the demographic and clinical characteristics of the groups were similar. Patients were young, had good ovarian reserve demonstrated by basal FSH levels, and, after ovarian stimulation, had a high number of oocytes collected, as expected for PCOS patients. In PCOS-NORM group, five patients presented

Table 1. Demographic and clinical characteristics of patients in the control and obese groups.

Parameters	PCOS-NORM group (M ± SD)	PCOS-OB group (M ± SD)	p ^a
Women age (years)	28.1 ± 6.0	32.0 ± 4.1	0.191
BMI (kg/m ²)	23.2 ± 1.9	34.0 ± 2.7	0.001
HOMA IR	2.5 ± 0.6	3.0 ± 0.3	0.097
Basal FSH (IU/ml)	5.4 ± 2.2	5.9 ± 1.9	0.757
Basal LH (IU/ml)	5.4 ± 3.0	5.3 ± 2.2	1.000
Fasting glucose (mg/dl)	91.1 ± 2.85	90 ± 4	0.679
Fasting insulin (μU/ml)	11.3 ± 2.63	13.7 ± 1.46	0.054
Free testosterone (pmol/l)	10.9 ± 2.4	11.1 ± 3.0	0.906
Total dose of FSH administered (IU)	2125 ± 163	2175 ± 116	0.586
Number of oocytes retrieved	19.7 ± 11.2	19.0 ± 12.5	0.854

BMI, body mass index; HOMA IR, Homeostasis Model Assessment–Insulin Resistance; FSH, follicle stimulating hormone; LH, luteinizing hormone; PCOS-NORM, Polycystic Ovary Syndrome–Normal weight group; PCOS-OB, Polycystic Ovary Syndrome–Obese group.
^aMann-Whitney *U* test.

two Rotterdam criteria and four patients presented all three criteria. In PCOS-OB group, four patients presented two Rotterdam criteria and two patients presented all three criteria (Supplemental Table 1). No OHSS occurred.

Gene expression profiles of CC samples isolated from PCOS-NORM and PCOS-OB patients

Three housekeeping genes—B2M, GAPDH, and HPRT1—were selected to normalize data based on transcription stability. All samples were tested for human genomic DNA contamination, reverse transcription control, and positive PCR control (data not shown). Three technical replicates were performed.

The general analysis of DE genes in PCOS-OB compared with those in PCOS-NORM women in the human insulin signaling pathway is presented in Figure 1. Interestingly, there were no genes downregulated in PCOS-OB patients compared with that in PCOS-NORM patients among the 11 significant DE genes. Table 2 shows the DE genes and respective log-FC and *p* values.

The analysis using Advaita Bio's iPathwayGuide combined enrichment (over-representation of

DE genes) and pathway topology (structure and dynamics of the entire pathway) to calculate a perturbation value for each gene. In our study, six DE genes caused perturbation of the insulin signaling pathway (Table 2). The perturbation in the pathway is highlighted in Figure 2, where we note that enrichment of those genes is involved in glucose uptake, glycolysis, protein synthesis, and cell proliferation/differentiation. Moreover, after eliminating pruning, we evaluated the biological processes related to DE genes in the PCOS-OB over PCOS-NORM groups. The overexpression of CBL and BRAF genes was associated with the activation of calcium ion binding.

Discussion

The PCOS is a complex multifactorial disorder with heterogeneous clinical features.^{22,23} The characterization of molecular markers in past years has identified genes involved in insulin resistance, steroidogenesis, and follicle development as the primary dysfunctional factors in this syndrome.²⁴ Obesity is clearly a clinical condition associated with PCOS incidence,⁷ usually related to hyperandrogenism.^{22,25} Here, we mapped the insulin signaling pathway in CCs from obese PCOS patients without clinical insulin resistance,




Figure 1. Volcano plot for human insulin signaling pathway DE gene expression distribution between the PCOS-OB and PCOS-NORM groups. The p value is plotted on the y-axis as the negative log of the p value. The x-axis shows the FC of each gene. The red circles represent the genes presenting $\log\text{-FC} \geq 0.6$ and adjusted p value = 0.05. FC, fold change; PCOS-NORM, Polycystic Ovary Syndrome-Normal weight group; PCOS-OB, Polycystic Ovary Syndrome-Obese group.

as evaluated by HOMA IR, and non-obese PCOS patients. Our results suggest that in the follicular environment, insulin resistance is transcriptionally present even in the absence of clinical signs in obese PCOS patients.

In vivo and *in vitro* studies show that insulin enhances growth and differentiation of theca and granulosa cells in the ovary.²⁶ The CCs are a subtype of granulosa cells essential to oocyte maturation, which respond to the luteinizing hormone (LH) trigger prompting an increase in calcium, which diffuses through gap junctions in a few minutes and into the oocyte, where a local amplification system spreads the signal all over the cell.²⁷ In addition, CCs are essential to cytoplasm maturation by promoting energetic metabolism and converting glucose into pyruvate, which can be metabolized to allow the oocyte to be fertilized, as well as early embryonic development.^{28,29}

The present study analyzed 84 pre-established genes related to the insulin signaling pathway in CCs of PCOS-OB and PCOS-NORM patients. Among these genes, 11 were significantly upregulated in the PCOS-OB patients in relation to the gene expression in the PCOS-NORM patients. The bioinformatics approach showed that six genes caused a perturbation in the insulin pathway (FBP1, SORBS1, CBL, BRAF, MTOR, and PCK2), and three of these genes that had higher $\log\text{-FC}$ (FBP1, CBL, and PCK2) are involved in glucose homeostasis. Calcium ion binding was the molecular function that was highlighted in the analysis. Calcium ion binding is also influenced by BRAF and CBL genes and presented higher FC in PCOS-OB patients over PCOS-NORM patients.

Our findings highlighted the perturbation of glucose homeostasis in CCs in obese PCOS patients compared with that in normal weight PCOS patients. The main gene associated with this function that was DE across groups was CBL. The function of CBL is related to insulin resistance induced by adipocytes in obese patients through inflammatory mechanisms.^{30,31} In a study evaluating the protein profile of visceral adipose tissue, CBL was shown to be responsible for signaling and regulation of insulin secretion, which was associated with the pathogenesis of diabetes mellitus type II.³² Considering the increased visceral adiposity in obese PCOS women and the relationship with the pathogenesis and phenotype of PCOS,³³ overexpression of the CBL gene in CCs observed in obese women in our study suggests that obesity can also affect the follicular environment and more specifically the insulin pathway. We suggest that insulin resistance can be present in the follicular environment, even in patients who do not have clinical insulin resistance indicated by HOMA IR.

The BRAF gene is an oncogene responsible for the protein kinase serine-threonine, which is involved in the delivery of intracellular signals directly related to cell proliferation in the MAPK (mitogen-activated protein kinase) pathway.³⁴ The CBL and BRAF genes were upregulated and associated with calcium ion binding in obese PCOS patients. Calcium oscillations are known to mediate a large number of physiological cell functions, including oocyte activation³⁵⁻³⁷ and mitotic cleavage.^{38,39}

Table 2. Genes upregulated in the CC of the PCOS-OB group compared with those in the PCOS-NORM group.

Gene description	Symbol	Fold change	<i>p</i> ^a
BCL2-like 1	BCL2L1	4.679	<0.0001
V-raf murine sarcoma viral oncogene homolog B1	BRAF	3.842	<0.0001
Cas-Br-M (murine) ecotropic retroviral transforming sequence	CBL	6.167	<0.0001
Docking protein 1, 62kDa (downstream of tyrosine kinase 1)	DOK1	4.625	<0.0001
Fructose-1,6-bisphosphatase 1	FBP1	5.298	<0.0001
Fibroblast growth factor receptor substrate 2	FRS2	4.102	<0.0001
Mechanistic target of rapamycin (serine/threonine kinase)	MTOR	3.888	<0.0001
Phosphoenolpyruvate carboxykinase 2 (mitochondrial)	PCK2	4.421	<0.0001
Ribosomal protein S6 kinase, 90 kDa, polypeptide 1	RPS6KA1	4.189	<0.0001
Sorbin and SH3 domain containing 1	SORBS1	3.583	<0.0001

CC, cumulus cell; PCOS-NORM, Polycystic Ovary Syndrome–Normal weight group; PCOS-OB, Polycystic Ovary Syndrome–Obese group
^aMann-Whitney *U* test.

The association of obesity and IVF outcomes is still controversial in the literature. Some authors believe that obesity is related to a worse prognosis,⁴⁰ and others have not shown clinical differences despite less favorable cycle characteristics.⁴¹ Obese patients may have a more activated calcium ion binding process to compensate for impairments in the micro-environment.

The oocyte uses pyruvate for cytoplasmic maturation,^{29,42} which is also the substrate for embryo metabolism during the initial development after fertilization.^{43,44} The gene PCK2 codes for a mitochondrial enzyme that catalyzes oxalacetate in phosphoenolpyruvate in the metabolic pathway of gluconeogenesis, exacerbating the production of glucose through pyruvate. Animal studies have shown that PCK2 overexpression predisposes the animal to obesity, and its knockout leads to hypoglycemia through Krebs cycle dysfunction.⁴⁵ Those data are in agreement with our findings as obese PCOS women have upregulated PCK2 such as FBP1, which codes for the fructose 1,6 diphosphatase enzyme and is responsible for gluconeogenesis.⁴⁶ Both genes are involved in glucose homeostasis perturbation.

Polymorphisms in SORBS1 (CBL associated protein – CAP) gene have been associated with

obesity and insulin resistance.^{47,48} In a study with the Korean population, SORBS1 polymorphism was also related with PCOS.⁴⁹ Moreover, in a comprehensive proteomic analysis, SORBS1 is upregulated in visceral adipose tissue from type 2 diabetes patients.³² In the insulin signaling pathway, SORBS1 acts as CBL-adaptor protein. When insulin binds to its receptor (IR), CBL is recruited by interaction with SORBS1 and, upon phosphorylation, dissociates from IR and migrates to plasma membrane. This complex is involved in GLUT4 translocation to cell membrane, which may interfere on glucose uptake.³² The interaction of CBL and SORBS1 (CAP) with GLUT4 is illustrated in Figure 2. In our study, CBL and SORBS1 are increased in obese patients, which may reflect in glucose uptake in granulosa cells, leading to important cellular metabolism dysfunction.

It could be speculated whether these deregulated genes and the consequent perturbation of glucose homeostasis in the CCs may be associated with the oocyte maturation deficiency observed in obese PCOS patients,⁵⁰ because the biochemical characteristics of the micro-environment of oocyte development (follicular fluid, CCs, and oocytes) play a critical role in determining oocyte quality and the subsequent potential to achieve




Figure 2. Insulin signaling pathway. The DE genes with FC higher than 3 are highlighted as perturbations in the pathway (FC is ≥ 3 and $p \leq 0.05$). DE, differentially expressed; FC, fold change.

fertilization and embryo development.⁵¹ Thus, the alterations observed in our study may not only reflect the metabolism status of CCs but are supposedly associated with the damage to oocyte development observed in PCOS obese patients.

The mammalian target of rapamycin (mTOR), a conserved serine/threonine protein kinase, promotes cell proliferation and inhibits apoptosis by the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signaling pathway.⁵² The insulin-mediated activation of PI3K/AKT/mTOR signaling induces p70S6K expression and increases S6BP and 4EBP1 phosphorylation, which promotes protein synthesis (Figure 2). The unbalance of this pathway is associated with impairment of follicular development and ovulation abnormalities, such as reduction of follicular growth and granulosa cell proliferation.⁵² Furthermore, the overexpression of the mTOR pathway can lead to insulin resistance, which is an important pathophysiological basis of PCOS.

The limitations of the study include low number of patients and the absence of follow-up, which

could be helpful to understand whether the follicular state modification is a prodrome to clinical manifestation of insulin resistance. The characteristic of this study limits the translation of our results to change the current medical practice, but highlights the need of attention on obese PCOS patients without clinical insulin resistance on how possible changes in follicular environment could affect clinical outcomes. Another point to be emphasized is that our study does not exclude the possibility that the same insulin signaling pathway alterations could not affect obese women without PCOS, due to the lack of an obese-control group without PCOS in our study. The aim of this study was not to compare the reproductive outcomes between the groups, because there is no statistical power for such analysis with our sample size, neither an adequate inclusion nor exclusion criterion to suggest that only the obesity factor, in association or not with PCOS, could be a determining factor.

In conclusion, a number of genes in the insulin signaling pathway that are involved in glucose homeostasis and calcium binding processes in the

follicular environment are upregulated in PCOS obese women who do not have clinical insulin resistance. Together, our findings and the related literature suggest that those alterations may be associated with the worse prognosis of follicular development and oocyte maturation observed in PCOS obese women.

Acknowledgements

The authors would like to thank all collaborators from Setor Integrado de Reprodução Humana—Universidade Federal de São Paulo (UNIFESP).

Author contributions

M.B.C. contributed to the study conception and design, acquisition, analysis and interpretation of data, and manuscript drafting; R.F. and T.C.S.B. contributed to study design, acquisition, and analysis of data; A.R.L. contributed to manuscript drafting and revision; and E.L.A.M. contributed to study conception and design, manuscript drafting, and revision.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was funded by Huntington Medicina Reprodutiva.

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

ORCID iD

Mauricio B. Chehin  <https://orcid.org/0000-0001-8589-6448>

Supplemental material

Supplemental material for this article is available online.

References

- Ehrmann DA. Polycystic ovary syndrome. *N Engl J Med* 2005; 352: 1223–1236.
- Carmina E, Rosato F, Janni A, *et al.* Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. *J Clin Endocrinol Metab* 2006; 91: 2–6.
- Goodarzi MO, Dumesic DA, Chazenbalk G, *et al.* Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. *Nat Rev Endocrinol* 2011; 7: 219–231.
- Adams J, Polson DW and Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. *Br Med J (Clin Res Ed)* 1986; 293: 355–359.
- Polson DW, Adams J, Wadsworth J, *et al.* Polycystic ovaries – a common finding in normal women. *Lancet* 1988; 1: 870–872.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. *Fertil Steril* 2004; 81: 19–25.
- Norman RJ, Dewailly D, Legro RS, *et al.* Polycystic ovary syndrome. *Lancet* 2007; 370: 685–697.
- Gambineri A, Pelusi C, Vicennati V, *et al.* Obesity and the polycystic ovary syndrome. *Int J Obes Relat Metab Disord* 2002; 26: 883–896.
- Urman B, Tiras B and Yakin K. Assisted reproduction in the treatment of polycystic ovarian syndrome. *Reprod Biomed Online* 2004; 8: 419–430.
- Kumar P, Nawani N, Malhotra N, *et al.* Assisted reproduction in polycystic ovarian disease: a multicentric trial in India. *J Hum Reprod Sci* 2013; 6: 49–53.
- Yan X, Shi YH, Sheng Y, *et al.* Pregnancy outcomes of patients with polycystic ovary syndrome undergoing in vitro fertilization and embryo transfer. *Zhonghua Fu Chan Ke Za Zhi* 2011; 46: 923–927.
- Bailey AP, Hawkins LK, Missmer SA, *et al.* Effect of body mass index on in vitro fertilization outcomes in women with polycystic ovary syndrome. *Am J Obstet Gynecol* 2014; 211: 163.e1–163.e6.
- Diamanti-Kandarakis E and Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. *Hum Reprod Update* 2005; 11: 631–643.
- Welt CK and Duran JM. Genetics of polycystic ovary syndrome. *Semin Reprod Med* 2014; 32: 177–182.
- Ben-Shlomo I and Younis JS. Basic research in PCOS: are we reaching new frontiers? *Reprod Biomed Online* 2014; 28: 669–683.
- Tata B, Mimouni NEH, Barbotin AL, *et al.* Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. *Nat Med* 2018; 24: 834–846.

17. Dadachanji R, Shaikh N, Khavale S, *et al.* PON1 polymorphisms are associated with polycystic ovary syndrome susceptibility, related traits, and PON1 activity in Indian women with the syndrome. *Fertil Steril* 2015; 104: 207–216.
18. Diamanti-Kandarakis E and Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocr Rev* 2012; 33: 981–1030.
19. Van Soom A, Tanghe S, De Pauw I, *et al.* Function of the cumulus oophorus before and during mammalian fertilization. *Reprod Domest Anim* 2002; 37: 144–151.
20. Stern SE, Williams K, Ferrannini E, *et al.* Identification of individuals with insulin resistance using routine clinical measurements. *Diabetes* 2005; 54: 333–339.
21. Kenigsberg S, Bentov Y, Chalifa-Caspi V, *et al.* Gene expression microarray profiles of cumulus cells in lean and overweight-obese polycystic ovary syndrome patients. *Mol Hum Reprod* 2009; 15: 89–103.
22. Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, *et al.* Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies. *Gynecol Endocrinol* 2016; 32: 343–353.
23. Teede H, Deeks A and Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. *BMC Med* 2010; 8: 41.
24. Poretsky L, Smith D, Seibel M, *et al.* Specific insulin binding sites in human ovary. *J Clin Endocrinol Metab* 1984; 59: 809–811.
25. Pasquali R and Gambineri A. New perspectives on the definition and management of polycystic ovary syndrome. *J Endocrinol Invest* 2018; 41: 1123–1135.
26. Poretsky L, Cataldo NA, Rosenwaks Z, *et al.* The insulin-related ovarian regulatory system in health and disease. *Endocr Rev* 1999; 20: 535–582.
27. Mattioli M and Barboni B. Signal transduction mechanism for LH in the cumulus-oocyte complex. *Mol Cell Endocrinol* 2000; 161: 19–23.
28. Vanderhyden BC and Armstrong DT. Role of cumulus cells and serum on the in vitro maturation, fertilization, and subsequent development of rat oocytes. *Biol Reprod* 1989; 40: 720–728.
29. Downs SM and Utecht AM. Metabolism of radiolabeled glucose by mouse oocytes and oocyte-cumulus cell complexes. *Biol Reprod* 1999; 60: 1446–1452.
30. Naramura M, Nadeau S, Mohapatra B, *et al.* Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. *Oncotarget* 2011; 2: 245–250.
31. Abe T, Hirasaka K, Kohno S, *et al.* Ubiquitin ligase Cbl-b and obesity-induced insulin resistance. *Endocr J* 2014; 61: 529–538.
32. Kim SJ, Chae S, Kim H, *et al.* A protein profile of visceral adipose tissues linked to early pathogenesis of type 2 diabetes mellitus. *Mol Cell Proteomics* 2014; 13: 811–822.
33. Chen L, Xu WM and Zhang D. Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome. *Fertil Steril* 2014; 102: 1167–1174.
34. Sithanandam G, Kolch W, Duh FM, *et al.* Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. *Oncogene* 1990; 5: 1775–1780.
35. Ebner T, Koster M, Shebl O, *et al.* Application of a ready-to-use calcium ionophore increases rates of fertilization and pregnancy in severe male factor infertility. *Fertil Steril* 2012; 98: 1432–1437.
36. Montag M, Koster M, van der Ven K, *et al.* The benefit of artificial oocyte activation is dependent on the fertilization rate in a previous treatment cycle. *Reprod Biomed Online* 2012; 24: 521–526.
37. Ebner T, Montag M, Montag M, *et al.* Live birth after artificial oocyte activation using a ready-to-use ionophore: a prospective multicentre study. *Reprod Biomed Online* 2015; 30: 359–365.
38. Ebner T, Oppelt P, Wober M, *et al.* Treatment with Ca²⁺ ionophore improves embryo development and outcome in cases with previous developmental problems: a prospective multicenter study. *Hum Reprod* 2015; 30: 97–102.
39. Berridge MJ, Bootman MD and Lipp P. Calcium – a life and death signal. *Nature* 1998; 395: 645–648.
40. Cui N, Wang H, Wang W, *et al.* Impact of body mass index on outcomes of in vitro fertilization/ intracytoplasmic sperm injection among polycystic ovarian syndrome patients. *Cell Physiol Biochem* 2016; 39: 1723–1734.
41. McCormick B, Thomas M, Maxwell R, *et al.* Effects of polycystic ovarian syndrome on in vitro fertilization-embryo transfer outcomes are

- influenced by body mass index. *Fertil Steril* 2008; 90: 2304–2309.
42. Downs SM, Humpherson PG and Leese HJ. Pyruvate utilization by mouse oocytes is influenced by meiotic status and the cumulus oophorus. *Mol Reprod Dev* 2002; 62: 113–123.
43. Leese HJ. Metabolism of the preimplantation embryo: 40 years on. *Reproduction* 2012; 143: 417–427.
44. Leese HJ. History of oocyte and embryo metabolism. *Reprod Fertil Dev* 2015; 27: 567–571.
45. Beale EG, Harvey BJ and Forest C. PCK1 and PCK2 as candidate diabetes and obesity genes. *Cell Biochem Biophys* 2007; 48: 89–95.
46. Visinoni S, Khalid NF, Joannides CN, *et al.* The role of liver fructose-1,6-bisphosphatase in regulating appetite and adiposity. *Diabetes* 2012; 61: 1122–1132.
47. Lin WH, Chiu KC, Chang HM, *et al.* Molecular scanning of the human sorbin and SH3-domain-containing-1 (SORBS1) gene: positive association of the T228A polymorphism with obesity and type 2 diabetes. *Hum Mol Genet* 2001; 10: 1753–1760.
48. San Millan JL, Corton M, Villuendas G, *et al.* Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. *J Clin Endocrinol Metab* 2004; 89: 2640–2646.
49. Park JM, Gu BH, Lee EJ, *et al.* A single nucleotide polymorphism in exon 7 of sorbin and SH3-domain-containing-1 (SORBS1) in Korean PCOS patients. *Mol Med Rep* 2008; 1: 93–97.
50. Sermondade N, Dupont C, Massart P, *et al.* Impact of polycystic ovary syndrome on oocyte and embryo quality. *Gynecol Obstet Fertil* 2013; 41: 27–30.
51. Revelli A, Delle Piane L, Casano S, *et al.* Follicular fluid content and oocyte quality: from single biochemical markers to metabolomics. *Reprod Biol Endocrinol* 2009; 7: 40.
52. Liu J, Wu DC, Qu LH, *et al.* The role of mTOR in ovarian neoplasms, polycystic ovary syndrome and ovarian aging. *Clin Anat* 2018; 31: 891–898.